

An imperfect tool: contact tracing could provide valuable reductions in COVID-19 transmission if good adherence can be achieved and maintained.

Emma L. Davis^{1,+,*}, Tim C. D. Lucas^{1,+}, Anna Borlase¹, Timothy M. Pollington^{1,3}, Sam Abbott², Diepreye Ayabina¹, Thomas Crellen¹, Joel Hellewell², Li Pi¹, CMMID COVID-19 working group⁶, Graham F. Medley⁴, T. Déirdre Hollingsworth^{1,†}, and Petra Klepac^{2,5,†}

¹Big Data Institute, University of Oxford, UK.

²Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, UK.

³MathSys CDT, University of Warwick, UK.

⁴Centre for Mathematical Modelling of Infectious Disease & Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.

⁵Department for Applied Mathematics and Theoretical Physics, University of Cambridge, UK.

⁶Full list of members in supplementary material.

*Corresponding author: Emma.Davis@bdi.ox.ac.uk

^{+,†}Contributed equally

1

Abstract

2 Emerging evidence suggests that contact tracing has had limited success in
3 the UK in reducing the R number across the COVID-19 pandemic. We
4 investigate potential pitfalls and areas for improvement by extending an ex-
5 isting branching process contact tracing model, adding diagnostic testing
6 and refining parameter estimates. Our results demonstrate that reporting
7 and adherence are the most important predictors of programme impact but
8 tracing coverage and speed plus diagnostic sensitivity also play an important
9 role. We conclude that well-implemented contact tracing could bring small
10 but potentially important benefits to controlling and preventing outbreaks,
11 providing up to a 15% reduction in R , and reaffirm that contact tracing is
12 not currently appropriate as the sole control measure.

13 Main

14 In December 2019, SARS-CoV-2, a novel coronavirus strain, was detected in
15 Hubei Province, China [1]. By 31 January 2020 the first UK cases of COVID-
16 19, the disease caused by SARS-CoV-2, were confirmed [2]. Initial modelling
17 studies indicated that fast and effective contact tracing could contain the UK
18 outbreak in most settings [3, 4]. However, by 20 March there were almost
19 4,000 confirmed cases nationwide [5], at which point the UK Government
20 scaled up physical distancing measures, including the closure of schools and
21 social venues, extending to heightened restrictions on non-essential travel,
22 outdoor activities and between-household social mixing [6]. Similar patterns
23 occurred in other countries [7, 8].

24 Throughout the pandemic, it has become obvious that the UK’s NHS Test
25 and Trace programme has not been as effective at reducing transmission as
26 originally hoped, with a recent financial report even suggesting it has made no
27 “measurable difference” to the course of the pandemic [9]. Results from the
28 Department of Health and Social Care (DHSC) are more flattering, but still
29 only conclude that contact tracing efforts reduced the R number by 2–5% in
30 October 2020 [10]. Speed of testing and tracing, poor integration with local
31 authorities and adherence to isolation have all been cited as possible reasons.
32 The head of NHS Test and Trace revealed in February 2021 that around
33 20,000 people a day had ignored isolation rules, despite being contacted by
34 them [11]. This number is based on 80% adherence to isolation, which is
35 optimistic compared to estimates from other surveys [12, 13, 14], and hence
36 may be a substantial underestimate.

37 The UK’s Test and Trace strategy has been continually updated through-
38 out the pandemic, but with minimal, if any, observed improvement in results.
39 A few elements have remained consistent throughout, such as traced contacts
40 only being allowed to access tests once symptomatic and requiring a posi-
41 tive test result before tracing an isolated individual’s contacts [15]. Current
42 methods are reliant on PCR testing, but there is growing discussion around
43 potential use of rapid lateral flow tests [16], which are considered to be sub-
44 stantially less sensitive [17].

45 Imperfect adherence to isolation and reporting and the innate difficulties
46 in identifying contacts will pose challenges for contact tracing, particularly
47 in crowded urban settings [18]. Therefore, evaluating both the limitations of
48 contact tracing and how to maximise its effectiveness could be crucial in pre-
49 venting an exponential rise in cases, which might see contact tracing capacity

50 rapidly exceeded and stricter physical distancing measures required [19].

51 Extending Hellewell *et al.*'s [3] UK-focused contact tracing study with
52 new insights could inform contact tracing strategy. Their key conclusion was
53 that highly effective contact tracing would be sufficient to control an initial
54 outbreak of COVID-19 in the UK, however subsequent evidence supports
55 much higher pre- and asymptomatic transmission rates than had initially
56 been considered. In particular, the original analysis only considered scenar-
57 ios with 0–10% of cases as asymptomatic and 0-30% of transmission from
58 symptomatic individuals occurring pre-symptoms, compared to more recent
59 estimates of 31–42.5% [20, 21, 22] and 44% [23] respectively. The focus on
60 speed in the UK contact tracing programme also requires a detailed assess-
61 ment of the associated trade-offs through mechanistic modelling of the testing
62 process. Up-to-date modelling studies are therefore needed to investigate the
63 feasibility of contact tracing and the conditions under which it is effective.

64 We use improved incubation period and serial interval estimates [24, 23,
65 25], consider imperfect self-reporting, adherence and tracing rates and simu-
66 late the use of diagnostic tests. We explore trade-offs between testing speed
67 and sensitivity, and investigate the limitations of contact tracing and in which
68 scenarios it is likely to be most effective.

69 **Results**

70 The underlying assumptions around the contact tracing logistics that have
71 been modelled and presented here are described in further detail in the Meth-
72 ods; Figure 5 provides a detailed schematic of the contact tracing process.

73 **Efficacy of contact tracing**

74 We used data from a UK-based survey to consider three adherence scenarios
75 [12]: a scenario with low self-reporting and poor adherence to isolation (rep-
76 resentative of the proportion of individuals who reported being fully adherent
77 to advice from Test and Trace); a scenario with good reporting and adher-
78 ence (representing those intending to be adherent to advice); and a scenario
79 with good reporting and boosted adherence (where additional incentives to
80 adhere to isolation are introduced).

81 Self-reporting and adherence can have a moderate-to-substantial impact
82 on the efficacy of Test and Trace (Figure 1). In the poor reporting & ad-
83 herence scenario, there is no observable benefit of scaling up the coverage of

84 contact tracing, or speeding up tracing. Increasing adherence and reporting
85 to intended compliance levels shows a clear benefit to increasing contact trac-
86 ing, with reductions in the outbreak risk and *effective reproduction number*
87 R (dependent on the proportion of contacts traced and the magnitude of
88 delays in testing and/or tracing) (Figures 1 & 2).

89 However, even when Test and Trace is able to identify and trace 80% of
90 contacts and compliance is good (good self-reporting, and adherence good or
91 better), the associated reduction in R is only 6–13%. If coverage is lower at
92 around 40% of contacts, the reduction is 6% or below. This highlights the
93 need for Test and Trace to be used as a supplemental measure, not as the
94 sole control strategy.

95 **Diagnostic trade-offs**

96 Assuming good compliance to Test and Test, we can investigate the com-
97 parative impact of a highly sensitive (95%) or poorly sensitive (65%) test
98 (Figure 3). There is a clear benefit to having a test with high sensitivity, and
99 the relative benefit increases with contact tracing coverage.

100 Although there is an observable benefit to increasing the speed of testing
101 and tracing, a two-day decrease in time to trace and obtain a test result, rep-
102 resenting the use of a rapid test, appears insufficient to make up for switching
103 from a 95% sensitive to a 65% sensitive test. However, the difference in prob-
104 ability of a large outbreak between instant testing with a 65% sensitive test
105 and a two-day delay with a 95% sensitive test is relatively small. Hence
106 conclusions around preferred test usage are likely to be sensitive to small
107 changes in testing delay or sensitivity.

108 **Outbreak thresholds for contact tracing**

109 By considering the total number of observed and unobserved cases in an
110 outbreak so far (Figure 4) we can evaluate the probability of a large outbreak
111 for a range of scenarios. It is hence possible to set thresholds for contact
112 tracing feasibility. For example, consider a scenario with average reporting
113 & adherence where 80% of contacts could be successfully traced. Then if the
114 desired outcome was keeping the probability of a large outbreak below 50%,
115 increasing testing and tracing speed from 2 days to instantaneous would raise
116 the threshold number of cases from 166 to 357—an increase of 115%.

117 Improving contact tracing coverage has a visible effect in all scenarios

118 presented, aside from those with poor reporting and adherence (left column).
119 In scenarios with average or boosted adherence for a fixed number of total
120 cases so far, speeding up tracing reduces the probability of a large outbreak
121 and increases the relative benefit of higher contact tracing coverage.

122 Conclusions

123 Our results provide insights into why contact tracing implementation has not
124 been as effective in reducing transmission as initially hoped in the UK. We
125 conclude that the largest likely factor is adherence to the various stages of
126 contact tracing and isolation, which is believed to be relatively poor [12].
127 However, if reasonable reporting and adherence can be achieved, then con-
128 tact tracing efficacy could be improved by increasing speed of test and tracing
129 or increasing the proportion of contacts traced in the majority of scenarios
130 considered. There are substantial behavioural challenges around improving
131 adherence, requiring consideration of why individuals do not, or cannot, ad-
132 here to guidance. Isolation of traced contacts and positive-testing individuals
133 is already legally required in England, so interventions would need to be tar-
134 geted around messaging, logistical support and financial incentives. Even
135 if good reporting and adherence, fast testing and tracing and identifying a
136 high proportion of contacts can be achieved, our results demonstrate that the
137 potential reduction in R is only around 10–15%. This confirms the emerging
138 conclusion in the field that the UK contact tracing programme, in its cur-
139 rent form, is ill-suited as the sole control strategy. However, more targeted
140 investigative contact tracing could still be beneficial for identification and
141 monitoring of new virus strains.

142 At this stage of the pandemic, there are more diagnostic tools available
143 than in the initial months. In particular, use of rapid lateral flow device
144 (LFD) tests is growing due to increased speed and reduced costs compared
145 to PCR alternatives. However, our results suggest that test sensitivity is still
146 important, with contact tracing using a 95% sensitive test that takes two
147 additional days performing better than an instantaneous 65% sensitive test.
148 This effect is seen in the presence of an assumption that negatively-testing
149 individuals are not immediately released from isolation guidance but if this
150 was not the case we would expect to see an even more marked reduction
151 in contact tracing efficacy when considering the faster lower-sensitivity test.
152 It is therefore vital to carefully consider the implications of changes in the
153 testing methods employed in contact tracing.

154 Our model assumes constant test sensitivity across an individual's in-
155 fected period, whereas a previous study shows that testing too early or late
156 after exposure can dramatically increase false negative rates [26]. While
157 assuming a fixed incubation period of 5 days, we have ignored temporal vari-
158 ation. Additionally, high between-person variance has been observed in the
159 natural history of infection [23]. It is therefore unclear what drives these
160 temporal changes in sensitivity or whether this temporal profile makes sense
161 on an individual basis. These simplifying assumptions mean we may be
162 over-estimating operational test sensitivity in some cases, leading to more
163 optimistic results around the impact of contact tracing. This reinforces the
164 conclusion that contact tracing is not currently appropriate as the sole control
165 measure.

166 We also assume the Negative Binomial dispersion, $k = 0.23$ [27], of sec-
167 ondary cases, does not vary with R_S due to different social distancing mea-
168 sures. This relationship is poorly characterised, but it is believed that social
169 distancing may increase k , leading to decreased heterogeneity in number of
170 contacts across the majority of the population due to an overall reduction
171 in mean contacts, paradoxically making outbreak control harder, although
172 this effect is expected to be cancelled out by the reduction in the mean [28].
173 Furthermore it is also possible that less heterogeneity in contacts may make
174 tracing of individual contacts more feasible, allowing for a higher coverage.

175 The vaccine roll-out is currently in progress in the UK, with over 50%
176 now believed to have COVID-19 antibodies through either vaccination or
177 prior infection [29]. This will have the effect of reducing R and, eventually,
178 when antibodies are sufficiently high, contact tracing may become viable as
179 the sole control measure for keeping R below 1.

180 Contact tracing improvements could include *secondary contact tracing* as
181 seen in Vietnam, i.e. tracing the 'contacts of contacts' of known cases, to get
182 ahead of the chain of transmission [30]. Backwards contact tracing, whilst
183 highly labour intensive, could also fill vital gaps where transmission links have
184 been missed by focusing on tracing back from known cases to identify parent
185 cases and potential super-spreaders [31]. As experience in contact tracing
186 develops, it may be possible to give contacts a prior probability of infection
187 (e.g. based on the contact duration and setting) and combine this with test
188 results to improve existing isolation protocol. Testing of asymptomatic con-
189 tacts would also allow tracing of currently hidden chains of infection, further
190 reducing transmission.

191 Overall, we conclude that well-implemented contact tracing could bring

192 small but potentially important benefits to controlling and preventing out-
193 breaks, providing up to a 15% reduction in R . Reporting and adherence are
194 the most important predictors of programme impact but tracing coverage
195 and speed also play an important role, as well as diagnostic sensitivity. In
196 line with a previous study [8], we have demonstrated that contact tracing
197 alone is highly unlikely to prevent large outbreaks unless used in combina-
198 tion with evidence-based physical distancing measures, including restrictions
199 on large gatherings.

200 **Methods**

201 In this extension of a previous COVID-19 branching process model [3], the
202 number of potential secondary cases generated by a primary case is drawn
203 from a Negative Binomial distribution. The exposure time for each case,
204 relative to infector onset, is drawn from a shifted Gamma distribution that
205 allows for pre-symptomatic transmission and is left-truncated to ensure sec-
206 ondary case exposure time is after the primary case exposure time. Secondary
207 cases are averted if the primary case is ‘quarantined’ at the time of infec-
208 tion, assuming within household segregation is possible. The probability of
209 quarantine depends on whether the primary case was traced, and adherence
210 to self-isolation recommendations, irrespective of the test result (Figure 5).
211 Each simulation was seeded with five index cases that are initially undetected
212 by the contact tracing system.

213 **Secondary case distribution**

214 A Negative Binomial distribution represented heterogeneity in onward trans-
215 mission due to factors such as individual contact patterns or infectiousness,
216 with the mean relating to the *effective reproduction number under physi-*
217 *cal distancing* R_S (taking values 1.1, 1.3 or 1.5) with a constant dispersion
218 parameter $k = 0.23$, taken from a study that used genome sequencing to
219 investigate the clustering of secondary cases [27]. This also represents a mid-
220 value among estimates, which vary widely from 0.1 (range: 0.05–0.2) [31] to
221 0.7 (range: 0.59–0.98) [32]. Here a smaller k represents greater heterogene-
222 ity in transmission and results in the majority of index cases leading to no
223 secondary infections, while a small proportion of individuals infect a large
224 number of secondary cases. All parameter estimates and references can be
225 found in Table 1.

226 **Generation interval**

227 The incubation period (time from exposure to symptoms) is assumed to fol-
228 low a Lognormal distribution with mean 1.43 and standard deviation 0.66
229 on the log scale [24]. Each new case is then infected at an exposure time
230 drawn from a Gamma-distributed infectivity profile (shape = 17.77, rate =
231 1.39 day^{-1} , shift = -13.0 days) relative to their infector's symptom onset.
232 If this time is before the infector's exposure then this value is rejected and
233 re-sampled to prevent negative generation intervals. This Gamma distribu-
234 tion has been fitted under these sampling assumptions to serial interval data
235 published by He *et al.* [23] using the `fitdistr` package in R and our resulting
236 distributions qualitatively match those presented in the original paper (see
237 Figure S1 in Supplementary File for more details). The exposure time is then
238 compared to the isolation times of the infector and cases are averted if the
239 infector is in isolation when the infection event would have happened. For
240 non-averted cases, symptom onset times are then drawn from the Lognor-
241 mal incubation period distribution and the probability of a case remaining
242 asymptomatic throughout their infected period is fixed at 31% [22].

243 **Contact tracing**

244 New cases are identified either through tracing contacts (like persons B &
245 D in Figure 5) of known cases or symptomatic individuals self-reporting to
246 the system, which we model as a two-stage process. Firstly, if an individual
247 is symptomatic (i.e. has a fever and/or dry persistent cough) but untraced
248 we assume that a combination of reduced social activity due to illness, and
249 awareness of COVID-19 prevention measures, results in a probability, a_1 of
250 self-isolation one day after symptom onset. Secondly, individuals who self-
251 isolate in this way then have a probability, a_2 , of contacting the tracing
252 programme and reporting their symptoms as a potential case (like person
253 A), which can be varied in the model.

254 Using data on UK adherence to the NHS Test and Trace programme from
255 the CORSAIR study [12], we characterised three levels of population compli-
256 ance. Firstly, as a lower bound, we considered the proportion of individuals
257 who reported complete adherence to guidance: 18.2% reported adhering fully
258 to isolation following onset of symptoms; 11.9% of symptomatic individuals
259 self-reported their case to Test and Trace; and 10.9% of traced individuals
260 isolated for the recommended duration. These reported figures were sub-

261 stantially lower than the intentional adherence reported by individuals who
262 had not yet developed symptoms or been traced, which was taken as a ‘good’
263 compliance scenario: 70% individuals said they would isolate following symp-
264 toms; 40–50% would self-report following onset; and 65% would isolate for
265 the full duration if contacted by Test and Trace. We also considered a sce-
266 nario with a boosted adherence to tracing of 90%.

267 Contact tracing is initiated where an existing case has been identified,
268 isolated and returned a positive test (person A). The time taken to get a
269 test result is either instant, 1 day or 2 days. The contacts of that individual
270 are then traced with 40%–100% coverage. If a contact is successfully traced
271 they will isolate with probability a_3 . This continues until either the out-
272 break exceeds 2000 cases, or there are no further cases, resulting in disease
273 extinction.

274 Testing

275 In simulations that include testing, we assume constant test sensitivities of
276 65% or 95%. The lower value aims to represent tests with poorer sensitivity,
277 such as the rapid lateral flow tests that are seeing increased usage in 2021,
278 based on estimates in the literature of 50.1–79.2% sensitivity [33, 34]. The
279 higher value represents the PCR tests that are available, with an estimated
280 94.8% sensitivity [34, 35]. Due to the nature of the branching process model,
281 only infected individuals are modelled so the impact of test specificity cannot
282 be assessed under these methods, although the implications would be related
283 to programme feasibility rather than efficacy. Current specificity estimates
284 for both types of test are believed to be reasonably high in comparison [36,
285 37, 38, 33, 34], with some estimates of close to 100%, but false positive tests
286 could lead to unnecessary negative socioeconomic impact under any scheme
287 requiring quarantine of healthy individuals.

288 When testing is included in the model, all individuals that either self-
289 report to the contact tracing system (person A in Figure 5), or are traced
290 contacts (persons B & D), are tested. From the moment a contact self-
291 reports or is identified through tracing, either a zero-, one- or two-day delay
292 is simulated before the test result is returned, chosen to be representative
293 of UK programme targets. If a positive test is returned, the individual’s
294 contacts are traced. If a negative test is returned, the individual is asked to
295 complete a precautionary quarantine period of 7 days from the beginning of
296 isolation.

297 **Simulation process**

298 Results presented are the combined output of 5,000 simulations for each pa-
299 rameter combination or scenario, and each simulation is run for a maximum
300 of 300 days. These results are used to derive the probability of a large out-
301 break given a range of conditions. A *large outbreak* is defined at 2,000 cases:
302 this threshold was chosen from experimental runs with a maximum of 5,000
303 cases and noting which of the simulated epidemics went extinct; 99% of ex-
304 tinctions occurred before reaching 2,000 cases. The model was written in R
305 with pair code review and unit tests [39]. The code is available from a public
306 GitHub repository (github.com/timcdlucas/ringbp).

Acknowledgments & funding sources

ELD, TC DL, AB, DA, LP, TMP, GFM & TDH gratefully acknowledge fund-
ing of the NTD Modelling Consortium (NTDMC) by the Bill & Melinda
Gates Foundation (BMGF) (grant n^o OPP1184344). ELD, LP & TDH grate-
fully acknowledge funding from the MRC COVID-19 UKRI/DHSC Rapid Re-
sponse grant MR/V028618/1 and JUNIPER Consortium (MR/V038613/1).
The following funding sources are acknowledged as providing funding for the
named authors. This research was partly funded by the Bill & Melinda Gates
Foundation (NTDMC: OPP1184344: GFM). This project has received fund-
ing from the European Union’s Horizon 2020 research and innovation pro-
gramme - project EpiPose (101003688: PK). Royal Society (RP/EA/180004:
PK). Wellcome Trust (210758/Z/18/Z: JH, SA). Views, opinions, assump-
tions or any other information set out in this article should not be attributed
to BMGF or any person connected with them. TC is funded by a Sir Henry
Wellcome Fellowship from the Wellcome Trust (215919/Z/19/Z). TMP’s
PhD is supported by the Engineering & Physical Sciences Research Coun-
cil, Medical Research Council and University of Warwick (EP/L015374/1)
and thanks Big Data Institute for hosting him. All funders had no role in
the study design, collection, analysis, interpretation of data, writing of the
report, or decision to submit the manuscript for publication.

CRedit contribution statement

Conceptualisation: ELD, TCDL, PK, GFM, TDH
Formal Analysis: ELD, TCDL
Funding acquisition: TDH
Investigation: ELD, TCDL, AB, TMP, LP, DA, TC
Methodology: ELD, TCDL
Software: ELD, TCDL, SA, JH
Validation: ELD, TCDL
Visualization: ELD, AB
Writing - original draft: ELD, TCDL
Writing - review & editing: All authors

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

1 Code Availability

The code used in this study is available in Zenodo with the DOI: 10.5281/zenodo.4752369.

2 Data Availability

The data that support the findings of this study are available in Zenodo with the DOI: 10.5281/zenodo.4752369.

References

- [1] South China Morning Post. Coronavirus: China's first confirmed COVID-19 case traced back to November 17. www.scmp.com/news/china/society/article/3074991/coronavirus-chinas-first-confirmed-covid-19-case-traced-back (2020). Accessed 2020-06-02.

- [2] The Guardian. Could COVID-19 have reached the UK earlier than thought? www.theguardian.com/world/2020/jun/01/spate-of-possible-uk-coronavirus-cases-from-2019-come-to-light (2020). Accessed 2020-06-02.
- [3] Hellewell, J. *et al.* Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. *The Lancet Global Health* (2020).
- [4] Keeling, M. J., Hollingsworth, T. D. & Read, J. M. Efficacy of contact tracing for the containment of the 2019 novel coronavirus (COVID-19). *J Epidemiol Community Health* **74**, 861–866 (2020).
- [5] Worldometer. Coronavirus UK summary. www.worldometers.info/coronavirus/country/uk (2020). Accessed: 2020-05-12.
- [6] GOV.UK. Coronavirus (COVID-19). www.gov.uk/coronavirus (2020). Accessed 2020-05-12.
- [7] Flaxman, S. *et al.* Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature* 1–5 (2020).
- [8] Giordano, G. *et al.* Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy. *Nature Medicine* 1–6 (2020).
- [9] Wise, J. Covid-19: NHS Test and Trace made no difference to the pandemic, says report. *BMJ* **372**, n663 (2021).
- [10] UK Department of Health and Social Care. The Rùm Model Technical Annex - an explainer. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/960898/RUM_model_technical_explainer_11-02-21.pdf (2021). Accessed: 2021-04-14.
- [11] Fancourt, D., Bu, F., Mak, H. W. & Steptoe, A. COVID-19 social study. *Results release* **15** (2020).
- [12] Smith, L. E. *et al.* Adherence to the test, trace, and isolate system in the uk: results from 37 nationally representative surveys. *bmj* **372** (2021).

- [13] Reicher, S. & Drury, J. Pandemic fatigue? how adherence to COVID-19 regulations has been misrepresented and why it matters. *BMJ* **372** (2021).
- [14] Smith, L. E. *et al.* Factors associated with adherence to self-isolation and lockdown measures in the UK: a cross-sectional survey. *Public Health* **187**, 41–52 (2020).
- [15] GOV.UK. NHS Test and Trace: what to do if you are contacted. <https://www.gov.uk/guidance/nhs-test-and-trace-how-it-works> (2021). Accessed 2021-03-11.
- [16] Crozier, A., Rajan, S., Buchan, I. & McKee, M. Put to the test: use of rapid testing technologies for COVID-19. *bmj* **372** (2021).
- [17] Wise, J. Covid-19: Lateral flow tests miss over half of cases, Liverpool pilot data show (2020).
- [18] Ferretti, L. *et al.* Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. *Science* **368** (2020).
- [19] Anderson, R. M., Heesterbeek, H., Klinkenberg, D. & Hollingsworth, T. D. How will country-based mitigation measures influence the course of the COVID-19 epidemic? *The Lancet* **395**, 931–934 (2020).
- [20] Mizumoto, K., Kagaya, K., Zarebski, A. & Chowell, G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Eurosurveillance* **25**, 2000180 (2020).
- [21] Lavezzo, E. *et al.* Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo. *Nature* **584**, 425–429 (2020).
- [22] Buitrago-Garcia, D. *et al.* Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. *PLoS medicine* **17**, e1003346 (2020).
- [23] He, X. *et al.* Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nature Medicine* 1–4 (2020).

- [24] Li, Q. *et al.* Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *New England Journal of Medicine* (2020).
- [25] Ganyani, T. *et al.* Estimating the generation interval for coronavirus disease (COVID-19) based on symptom onset data, March 2020. *Euro-surveillance* **25**, 2000257 (2020).
- [26] Kucirka, L. M., Lauer, S. A., Laeyendecker, O., Boon, D. & Lessler, J. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. *Annals of Internal Medicine* (2020).
- [27] Wang, L. *et al.* Inference of person-to-person transmission of COVID-19 reveals hidden super-spreading events during the early outbreak phase. *Nature communications* **11**, 1–6 (2020).
- [28] Lloyd-Smith, J. O., Schreiber, S. J., Kopp, P. E. & Getz, W. M. Super-spreading and the effect of individual variation on disease emergence. *Nature* **438**, 355–359 (2005).
- [29] Office of National Statistics. Coronavirus (COVID-19) infection survey, antibody and vaccination data for the UK: 30 March 2021. www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsurveyantibodydatafortheuk/30march2021#main-points (2021). Accessed: 2021-03-31.
- [30] Le, S. M. Containing the coronavirus (COVID-19): Lessons from Vietnam. <https://blogs.worldbank.org/health/containing-coronavirus-covid-19-lessons-vietnam>. (2020). Accessed: 2020-06-03.
- [31] Endo, A., Abbott, S., Kucharski, A. J., Funk, S. *et al.* Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China. *Wellcome Open Research* **5**, 67 (2020).
- [32] He, D. *et al.* Low dispersion in the infectiousness of COVID-19 cases implies difficulty in control. *BMC Public Health* **20**, 1–4 (2020).

- [33] Torjesen, I. COVID-19: How the UK is using lateral flow tests in the pandemic. *bmj* **372** (2021).
- [34] UK Department of Health and Social Care. Lateral flow device specificity in phase 4 (post marketing) surveillance. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/968095/lateral-flow-device-specificity-in-phase-4.pdf (2021). Accessed: 2021-04-19.
- [35] van Kasteren, P. *et al.* Comparison of seven commercial RT-PCR diagnostic kits for COVID-19. *Journal of Clinical Virology* **128** (2020).
- [36] Nalla, A. K. *et al.* Comparative performance of SARS-CoV-2 detection assays using seven different primer-probe sets and one assay kit. *Journal of Clinical Microbiology* **58** (2020).
- [37] Zitek, T. The appropriate use of testing for COVID-19. *Western Journal of Emergency Medicine* **21**, 470 (2020).
- [38] Grassly, N. *et al.* Report 16: Role of testing in COVID-19 control. *Imperial College London* (2020).
- [39] Lucas, T. C., Pollington, T. M., Davis, E. L. & Hollingsworth, T. D. Responsible modelling: Unit testing for infectious disease epidemiology. *Epidemics* 100425 (2020).
- [40] Menni, C. *et al.* Real-time tracking of self-reported symptoms to predict potential COVID-19. *Nature Medicine* 1–4 (2020).
- [41] Davis, E. L. & Lucas, T. C. *et al.* TTI Analysis Code and Data. *Zenodo* v1.1 (Version 1.1) [Computer software]. <https://doi.org/10.5281/zenodo.4752369> (2021, May 6).

Parameter	Values	Refs
Number of initial cases	5	
Effective reproduction number under physical distancing, R_S	1.3, 1.5	
Dispersion of R_S , k	0.23	[27]
Proportion asymptomatic	31%	[22]
Delay: onset to isolation	1 day	
Incubation period (Lognormal)	mean log: 1.43	[24, 23]
Incubation period (Lognormal)	sd log: 0.66	[24, 23]
Infection time (Gamma)	shape: 17.77	[23]
Infection time (Gamma)	rate: 1.39 day ⁻¹	fitted from [23]
Infection time shift	-13.0 days	[23]
Untraced self-isolation prob.	18.2%, 70%	based on [12]
Self-reporting probability	11.9%, 50%	based on [12]
Traced isolation adherence prob.	10.9%, 65%, 90%	[12]
Contact tracing coverage	0-80%	
Test sensitivity	65%, 95%	[26, 40, 35]
Time to test result (days)	0, 2	
Isolation duration if -ve test	7 days	

Table 1: Model parameters values/ranges. Parameters taken from the literature are fixed and for other parameters a range of values are explored.




Figure 1: **Probability of a large outbreak.** Probability of a large outbreak (>2000 cases) for different Test and Trace compliance scenarios for instant testing and tracing (dashed, green) and a 2-day delay (solid, orange), assuming 95% test sensitivity. Poor reporting & adherence (top): 11.9% self-reporting; 18.2% isolation on symptoms; 10.9% isolation on tracing. Good reporting & adherence (middle): 50% self-reporting; 70% isolation on symptoms; 65% isolation on tracing. Boosted adherence (bottom): 50% self-reporting; 70% isolation on symptoms; 90% isolation on tracing. Left: $R_s = 1.3$. Right: $R_s = 1.5$. Error bars: 99% confidence intervals from output variation of 5,000 simulations. TTI = test, trace and isolate.




Figure 2: **Contact tracing efficacy.** Percentage reduction in the effective reproductive number, R , for different Test and Trace compliance scenarios. For instant testing and tracing (dashed, green) or a 2-day delay (solid, orange). Assuming 95% test sensitivity. Poor reporting & adherence (top): 11.9% self-reporting; 18.2% isolation on symptoms; 10.9% isolation on tracing. Good reporting & adherence (middle): 50% self-reporting; 70% isolation on symptoms; 65% isolation on tracing. Good reporting & high adherence (bottom): 50% self-reporting; 70% isolation on symptoms; 90% isolation on tracing. Left: $R_s = 1.3$. Right: $R_s = 1.5$. Combined results of 5,000 simulations.




Figure 3: **Diagnostic trade-offs.** Probability of a large outbreak (>2000 cases), by contact tracing coverage, for instant testing and tracing (green), a 1-day delay (orange) and a 2-day delay (green) with either 65% test sensitivity (dashed) or 95% (solid). Left: $R_s = 1.3$. Right: $R_s = 1.5$. Assuming good compliance (50% self-reporting, 70% isolation on symptoms, 65% isolation on tracing) and $R_s = 1.3$. Error bars: 95% confidence intervals from output variation of 5,000 simulations.




Figure 4: **Outbreak thresholds.** Probability of a large outbreak (>2000 cases) by total number of cases so far (observed and unobserved). Sensitivity = 95%, self-reporting proportion = 50%, time to test from isolation = 1 day. Error windows: 95% confidence intervals from output variation of 5,000 simulations.










Figure 5: **Contact tracing schematic.** Overview of the contact tracing process implemented in our model. **Person A** isolates and self-reports to the contact tracing programme with some delay after symptom onset, by which time they have infected Persons B, C and D. When Person A self-reports they isolate and are tested, a positive result initiates contact tracing. **Person B** was infected by A prior to their symptom onset and is detected by tracing after some delay. After isolating they are tested, with a false negative result. This leads to B either a) stopping isolation immediately or b) finishing a minimum 7 day isolation period. Both may allow new onward transmission. **Person C** was infected by A but not traced as a contact. Person C does not develop symptoms but is infectious, leading to missed transmission. **Person D** is traced and tested. The test for D returns positive, meaning that D remains isolated, halting this chain of transmission.





$R_0 = 1.3$  $R_0 = 1.5$ 

Prob. large outbreak





good reporting & adherence







boosted adherence

Contact tracing coverage

TTI delay: -- instant tracing — 2-day delay


$R_0 = 1.3$  $R_0 = 1.5$ 

% reduction in R



Contact tracing coverage

TTI delay: instant tracing 2-day delay

$R_0 = 1.3$  $R_0 = 1.5$ 